West Pharmaceutical Services (WST) Financials
$344.25
As on 10-Sep-2026 16:02EDT
Market cap
$24,120 Mln
Revenue (TTM)
$3,327 Mln
P/E Ratio
43.9
P/B Ratio
8
Div. Yield
0.3 %
Income Statement ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Operating Revenue
|
3,326.50
|
3,073.70
|
2,892.70
|
2,951.10
|
2,885.50
|
2,830.70
|
|||||
|
Cost of Revenue
|
2,103.50
|
1,970.40
|
1,890.50
|
1,818.40
|
1,746.60
|
1,657.30
|
|||||
|
Gross Profit
|
1,223.00
|
1,103.30
|
1,002.20
|
1,132.70
|
1,138.90
|
1,173.40
|
|||||
|
Operating Expenses
|
536.00
|
485.90
|
407.60
|
421.80
|
375.40
|
414.70
|
|||||
|
Operating Profit (EBIT)
|
686.50
|
617.40
|
594.60
|
710.90
|
763.50
|
758.70
|
|||||
|
Other Income
|
--
|
--
|
--
|
--
|
-25.50
|
24.90
|
|||||
|
Profit before Tax
|
699.60
|
615.30
|
600.20
|
715.70
|
700.60
|
769.00
|
|||||
|
Provision for Tax
|
144.20
|
121.60
|
107.50
|
122.30
|
114.70
|
107.20
|
|||||
|
Profit after Tax (Net Income)
|
564.90
|
493.70
|
492.70
|
593.40
|
585.90
|
661.80
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Consolidated Profit
|
272.10
|
493.70
|
492.70
|
593.40
|
585.90
|
661.80
|
Liabilities ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Shareholder's Funds
|
2,990.20
|
3,176.00
|
2,682.30
|
2,881.00
|
2,684.90
|
2,335.40
|
|||||
|
Minority Interest
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Non-Current Liabilities
|
445.70
|
439.10
|
410.70
|
276.70
|
412.90
|
384.30
|
|||||
|
Current Liabilities
|
640.50
|
654.90
|
550.40
|
671.80
|
519.00
|
594.10
|
|||||
|
Total Liabilities
|
4,716.90
|
4,270.00
|
3,643.40
|
3,829.50
|
3,616.80
|
3,313.80
|
Assets ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Non-Current Assets
|
2,268.90
|
2,291.90
|
2,105.40
|
1,893.10
|
1,697.30
|
1,571.80
|
|||||
|
Current Assets
|
1,807.50
|
1,978.20
|
1,538.10
|
1,936.40
|
1,919.50
|
1,742.00
|
|||||
|
Total Assets
|
4,716.90
|
4,270.00
|
3,643.40
|
3,829.50
|
3,616.80
|
3,313.80
|
|||||
|
Total Debt*
|
312.10
|
416.70
|
305.30
|
309.00
|
317.90
|
325.30
|
|||||
|
Net Current Assets
|
1,167.00
|
1,323.30
|
987.70
|
1,264.60
|
1,400.50
|
1,147.90
|
Cashflow ($ Mln) |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Cash From Operating Activities
|
--
|
754.80
|
653.40
|
776.50
|
724.00
|
584.00
|
|||||
|
Cash Flow from Investing Activities
|
--
|
-285.90
|
-378.70
|
-368.70
|
-288.20
|
-253.10
|
|||||
|
Cash from Financing Activities
|
--
|
-185.10
|
-622.60
|
-459.60
|
-293.60
|
-168.10
|
|||||
|
Net Cash Inflow / Outflow
|
--
|
--
|
--
|
--
|
142.20
|
147.10
|
Financials Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Adjusted EPS ($)
|
7.82
|
6.79
|
6.69
|
7.91
|
7.75
|
8.66
|
|||||
|
Cash EPS ($)
|
--
|
9.15
|
8.79
|
9.74
|
9.35
|
10.26
|
|||||
|
Adjusted Book Value ($)
|
--
|
43.69
|
36.39
|
38.41
|
35.51
|
30.57
|
|||||
|
Dividend per Share ($)
|
--
|
--
|
--
|
--
|
--
|
--
|
|||||
|
Cash Flow per Share ($)
|
--
|
10.38
|
8.87
|
10.35
|
9.58
|
7.64
|
|||||
|
Free Cash Flow per Share ($)
|
--
|
6.45
|
3.75
|
5.53
|
5.81
|
4.33
|
Profitability Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
ROCE (%)
|
--
|
15.01
|
15.95
|
19.16
|
20.69
|
27.34
|
|||||
|
ROE (%)
|
18.32
|
16.85
|
17.71
|
21.32
|
23.34
|
31.59
|
|||||
|
ROA (%)
|
12.18
|
12.48
|
13.19
|
15.94
|
16.91
|
21.67
|
|||||
|
EBIT Margin (%)
|
15.35
|
19.49
|
20.34
|
23.95
|
23.83
|
26.76
|
|||||
|
Net Margin (%)
|
16.98
|
16.06
|
17.03
|
20.11
|
20.49
|
23.18
|
|||||
|
Cash Profit Margin (%)
|
--
|
--
|
--
|
--
|
--
|
--
|
Growth Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Revenue Growth (%)
|
12.39
|
0.06
|
-0.02
|
0.02
|
0.02
|
0.32
|
|||||
|
EBIT Growth (%)
|
-14.65
|
1.84
|
-16.75
|
2.81
|
-9.23
|
84.82
|
|||||
|
Net Profit Growth (%)
|
15.83
|
0.20
|
-16.97
|
1.28
|
-11.47
|
91.16
|
|||||
|
EPS Growth (%)
|
17.44
|
0.02
|
-0.16
|
0.02
|
-0.11
|
0.90
|
|||||
|
Book Value Growth (%)
|
4.23
|
--
|
--
|
--
|
--
|
--
|
Valuation Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Price / Earnings
|
43.88
|
40.52
|
49.00
|
44.50
|
30.37
|
54.14
|
|||||
|
Price / Book Value
|
7.97
|
6.30
|
9.00
|
9.17
|
6.63
|
15.34
|
|||||
|
Dividend Yield (%)
|
0.25
|
--
|
--
|
--
|
--
|
--
|
|||||
|
EV/EBITDA
|
26.96
|
27.13
|
32.22
|
30.64
|
21.30
|
40.24
|
|||||
|
Close Price ($)
|
359.00
|
275.14
|
327.56
|
352.12
|
235.35
|
469.01
|
|||||
|
High Price ($)
|
359.66
|
348.90
|
413.70
|
415.73
|
472.55
|
475.35
|
|||||
|
Low Price ($)
|
206.80
|
187.43
|
265.00
|
225.66
|
206.19
|
253.86
|
|||||
|
Market Cap ($ Cr)
|
24,119.89
|
--
|
--
|
--
|
--
|
--
|
Solvency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debt to Equity
|
0.07
|
0.13
|
0.11
|
0.11
|
0.12
|
0.14
|
|||||
|
Short term debt to equity ratio
|
0.01
|
0.01
|
0.01
|
0.05
|
0.01
|
0.02
|
|||||
|
Current Ratio
|
2.82
|
3.02
|
2.79
|
2.88
|
3.70
|
2.93
|
|||||
|
Quick Ratio
|
2.12
|
2.34
|
2.11
|
2.24
|
2.90
|
2.30
|
|||||
|
Interest Coverage
|
71.67
|
998.67
|
202.90
|
80.32
|
90.46
|
89.11
|
Operating Efficiency Ratios |
TTM | Dec-25 | Dec-24 | Dec-23 | Dec-22 | Dec-21 | Dec-20 | Dec-19 | Dec-18 | Dec-17 | Dec-16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Debtors to sales (%)
|
21.40
|
18.69
|
19.10
|
17.35
|
17.58
|
17.27
|
|||||
|
Asset Turnover
|
0.72
|
0.78
|
0.77
|
0.79
|
0.83
|
0.93
|
|||||
|
Receivable days
|
--
|
66.96
|
67.21
|
63.08
|
63.06
|
56.41
|
|||||
|
Inventory Days
|
--
|
76.08
|
78.41
|
85.32
|
82.94
|
77.10
|
|||||
|
Payable days
|
--
|
45.69
|
46.53
|
45.98
|
46.80
|
49.07
|
|||||
|
Cash Conversion Cycle
|
--
|
97.35
|
99.08
|
102.42
|
99.20
|
84.44
|